WASHINGTON, July 28 /PRNewswire-USNewswire/ — In
FDLI’s latest monograph, Selling Pharmaceuticals and Biologics
to the Federal Government: Federal Supply Schedule and Federal
Pricing Requirements, Joy
Sturm, Allison Pugsley and
Stephen A. Smyers of Hogan
Lovells US LLP detail how pharmaceutical and biologics
manufacturers can deal effectively with government contracting
requirements and price calculation requirements. The 73-page
monograph (Volume 1, #5) succinctly describes how a manufacturer’s
commercial pricing decisions can have a significant impact on
product pricing in the federal marketplace and, thus, on a drug or
biologics company’s bottom line.
As the monograph notes, manufacturers who seek to receive
federal funds under certain Medicaid and Medicare programs must
agree to participate in the Federal Supply Schedule (FSS) and
Veterans Health Care Act of 1992 (VHCA) contracting and pricing
programs. Increased federal enforcement efforts surrounding these
programs, coupled with the recent extension of the VHCA federal
pricing requirements to the Department of Defense’s nationwide
TRICARE pharmacy program, have stimulated manufacturers — of
all sizes — to place additional emphasis on their federal
contracting and pricing functions, according to the monograph.
This monograph provides lawyers, business leaders and
pharmaceutical and biologics decision-makers with a user-friendly
understanding of the mechanics of pricing calculations and federal
contracting requirements; how common commercial pricing and
discounting arrangements can affect the prices that a company must
charge the government for its drugs and biologics; and how to spot
issues and develop strategic thinking to minimize compl
‘/>”/>
